APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

CRISPR and CRISPR-Associated (Cas) Genes

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

Selected research

Market Outlook & Growth Opportunities

Global CRISPR and CRISPR-Associated (Cas) Genes Market Outlook and Growth Opportunities 2026

Report ID 17389391042 January 2026196 pages

Choose your research edition.

Industry ResearchCRISPR and CRISPR-Associated (Cas) Genes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal CRISPR and CRISPR-Associated (Cas) Genes Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CRISPR and CRISPR-Associated (Cas) Genes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CRISPR and CRISPR-Associated (Cas) Genes Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal CRISPR and CRISPR-Associated (Cas) Genes Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Read the full market overview

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.

CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

This report provides an overview of the global CRISPR and CRISPR-Associated (Cas) Genes market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CRISPR and CRISPR-Associated (Cas) Genes and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CRISPR and CRISPR-Associated (Cas) Genes revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CRISPR and CRISPR-Associated (Cas) Genes market.

CRISPR and CRISPR-Associated (Cas) Genes Segment by Company

Thermo Fisher Scientific

Editas Medicine

Caribou Biosciences

CRISPR therapeutics

Intellia therapeutics, Inc.

Cellectis

Horizon Discovery Plc

Sigma Aldrich

Precision Biosciences

Genscript

Sangamo Biosciences Inc.

Lonza Group Limited

Integrated DNA Technologies

New England Biolabs

Origene Technologies

CRISPR and CRISPR-Associated (Cas) Genes Segment by Type

Genome Editing

Genetic engineering

gRNA Database/Gene Librar

CRISPR Plasmid

Human Stem Cells

Genetically Modified Organisms/Crops

Cell Line Engineering

CRISPR and CRISPR-Associated (Cas) Genes Segment by Application

Biotechnology Companies

Pharmaceutical Companies

Academic Institutes

Research and Development Institutes

CRISPR and CRISPR-Associated (Cas) Genes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CRISPR and CRISPR-Associated (Cas) Genes status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CRISPR and CRISPR-Associated (Cas) Genes key companies, revenue, market share, and recent developments.

3. To split the CRISPR and CRISPR-Associated (Cas) Genes breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CRISPR and CRISPR-Associated (Cas) Genes market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CRISPR and CRISPR-Associated (Cas) Genes significant trends, drivers, influence factors in global and regions.

6. To analyze CRISPR and CRISPR-Associated (Cas) Genes competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CRISPR and CRISPR-Associated (Cas) Genes industry.

Chapter 3: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CRISPR and CRISPR-Associated (Cas) Genes in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends Table 2. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers Table 3. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges Table 4. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints Table 5. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Company (2021-2026) Table 7. Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CRISPR and CRISPR-Associated (Cas) Genes Key Company Manufacturing Base & Headquarters Table 9. Global CRISPR and CRISPR-Associated (Cas) Genes Company, Product Type & Application Table 10. Global CRISPR and CRISPR-Associated (Cas) Genes Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CRISPR and CRISPR-Associated (Cas) Genes by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Genome Editing Table 15. Significant Companies of Genetic engineering Table 16. Significant Companies of gRNA Database/Gene Librar Table 17. Significant Companies of CRISPR Plasmid Table 18. Significant Companies of Human Stem Cells Table 19. Significant Companies of Genetically Modified Organisms/Crops Table 20. Significant Companies of Cell Line Engineering Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2021-2026) Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Biotechnology Companies Table 27. Significant Companies of Pharmaceutical Companies Table 28. Significant Companies of Academic Institutes Table 29. Significant Companies of Research and Development Institutes Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2021-2026) Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2027-2032) Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2021-2026) Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region (2027-2032) Table 40. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2021-2026) Table 43. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Market Share by Country (2027-2032) Table 45. Thermo Fisher Scientific Company Information Table 46. Thermo Fisher Scientific Business Overview Table 47. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 49. Thermo Fisher Scientific Recent Development Table 50. Editas Medicine Company Information Table 51. Editas Medicine Business Overview Table 52. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 54. Editas Medicine Recent Development Table 55. Caribou Biosciences Company Information Table 56. Caribou Biosciences Business Overview Table 57. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 59. Caribou Biosciences Recent Development Table 60. CRISPR therapeutics Company Information Table 61. CRISPR therapeutics Business Overview Table 62. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 64. CRISPR therapeutics Recent Development Table 65. Intellia therapeutics, Inc. Company Information Table 66. Intellia therapeutics, Inc. Business Overview Table 67. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 69. Intellia therapeutics, Inc. Recent Development Table 70. Cellectis Company Information Table 71. Cellectis Business Overview Table 72. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 74. Cellectis Recent Development Table 75. Horizon Discovery Plc Company Information Table 76. Horizon Discovery Plc Business Overview Table 77. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 79. Horizon Discovery Plc Recent Development Table 80. Sigma Aldrich Company Information Table 81. Sigma Aldrich Business Overview Table 82. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 84. Sigma Aldrich Recent Development Table 85. Precision Biosciences Company Information Table 86. Precision Biosciences Business Overview Table 87. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 89. Precision Biosciences Recent Development Table 90. Genscript Company Information Table 91. Genscript Business Overview Table 92. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 94. Genscript Recent Development Table 95. Sangamo Biosciences Inc. Company Information Table 96. Sangamo Biosciences Inc. Business Overview Table 97. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 99. Sangamo Biosciences Inc. Recent Development Table 100. Lonza Group Limited Company Information Table 101. Lonza Group Limited Business Overview Table 102. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 104. Lonza Group Limited Recent Development Table 105. Integrated DNA Technologies Company Information Table 106. Integrated DNA Technologies Business Overview Table 107. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 109. Integrated DNA Technologies Recent Development Table 110. New England Biolabs Company Information Table 111. New England Biolabs Business Overview Table 112. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 114. New England Biolabs Recent Development Table 115. Origene Technologies Company Information Table 116. Origene Technologies Business Overview Table 117. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 119. Origene Technologies Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Product Image Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032) & (US$ Million) Figure 4. Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Genome Editing Image Figure 8. Genetic engineering Image Figure 9. gRNA Database/Gene Librar Image Figure 10. CRISPR Plasmid Image Figure 11. Human Stem Cells Image Figure 12. Genetically Modified Organisms/Crops Image Figure 13. Cell Line Engineering Image Figure 14. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2021-2032) Figure 17. Biotechnology Companies Image Figure 18. Pharmaceutical Companies Image Figure 19. Academic Institutes Image Figure 20. Research and Development Institutes Image Figure 21. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2021-2032) Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032) & (US$ Million) Figure 27. North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032) & (US$ Million) Figure 29. Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032) & (US$ Million) Figure 33. South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Genome Editing
  • Genetic engineering
  • gRNA Database/Gene Librar
  • CRISPR Plasmid
  • Human Stem Cells
  • Genetically Modified Organisms/Crops
  • Cell Line Engineering
Applications
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic Institutes
  • Research and Development Institutes
Companies covered
  • Thermo Fisher Scientific
  • Editas Medicine
  • Caribou Biosciences
  • CRISPR therapeutics
  • Intellia therapeutics, Inc.
  • Cellectis
  • Horizon Discovery Plc
  • Sigma Aldrich
  • Precision Biosciences
  • Genscript
  • Sangamo Biosciences Inc.
  • Lonza Group Limited
  • Integrated DNA Technologies
  • New England Biolabs
  • Origene Technologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CRISPR and CRISPR-Associated (Cas) Genes Market Dynamics
  1. 2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
  2. 2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
  3. 2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
  4. 2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
3 CRISPR and CRISPR-Associated (Cas) Genes Market by Company
  1. 3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Company Revenue Ranking in 2025
  2. 3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Company (2021-2026)
  3. 3.3 Global CRISPR and CRISPR-Associated (Cas) Genes Company Ranking (2024-2026)
  4. 3.4 Global CRISPR and CRISPR-Associated (Cas) Genes Company Manufacturing Base and Headquarters
  5. 3.5 Global CRISPR and CRISPR-Associated (Cas) Genes Company Product Type and Application
  6. 3.6 Global CRISPR and CRISPR-Associated (Cas) Genes Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CRISPR and CRISPR-Associated (Cas) Genes Market by Type
  1. 4.1 CRISPR and CRISPR-Associated (Cas) Genes Type Introduction
  2. 4.1.1 Genome Editing
  3. 4.1.2 Genetic engineering
  4. 4.1.3 gRNA Database/Gene Librar
  5. 4.1.4 CRISPR Plasmid
  6. 4.1.5 Human Stem Cells
  7. 4.1.6 Genetically Modified Organisms/Crops
  8. 4.1.7 Cell Line Engineering
  9. 4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type
  10. 4.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Type (2021-2032)
  12. 4.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type (2021-2032)
5 CRISPR and CRISPR-Associated (Cas) Genes Market by Application
  1. 5.1 CRISPR and CRISPR-Associated (Cas) Genes Application Introduction
  2. 5.1.1 Biotechnology Companies
  3. 5.1.2 Pharmaceutical Companies
  4. 5.1.3 Academic Institutes
  5. 5.1.4 Research and Development Institutes
  6. 5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application
  7. 5.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Application (2021-2032)
  9. 5.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application (2021-2032)
6 CRISPR and CRISPR-Associated (Cas) Genes Regional Value Analysis
  1. 6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2021-2032)
  3. 6.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region: 2021-2026
  4. 6.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032)
  7. 6.3.2 North America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032)
  10. 6.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032)
  16. 6.6.2 South America CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Country, 2025 VS 2032
7 CRISPR and CRISPR-Associated (Cas) Genes Country-level Value Analysis
  1. 7.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2021-2032)
  3. 7.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2021-2026)
  4. 7.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CRISPR and CRISPR-Associated (Cas) Genes Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CRISPR and CRISPR-Associated (Cas) Genes Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Editas Medicine
  8. 8.2.1 Editas Medicine Company Information
  9. 8.2.2 Editas Medicine Business Overview
  10. 8.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  12. 8.2.5 Editas Medicine Recent Developments
  13. 8.3 Caribou Biosciences
  14. 8.3.1 Caribou Biosciences Company Information
  15. 8.3.2 Caribou Biosciences Business Overview
  16. 8.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  18. 8.3.5 Caribou Biosciences Recent Developments
  19. 8.4 CRISPR therapeutics
  20. 8.4.1 CRISPR therapeutics Company Information
  21. 8.4.2 CRISPR therapeutics Business Overview
  22. 8.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  24. 8.4.5 CRISPR therapeutics Recent Developments
  25. 8.5 Intellia therapeutics, Inc.
  26. 8.5.1 Intellia therapeutics, Inc. Company Information
  27. 8.5.2 Intellia therapeutics, Inc. Business Overview
  28. 8.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  30. 8.5.5 Intellia therapeutics, Inc. Recent Developments
  31. 8.6 Cellectis
  32. 8.6.1 Cellectis Company Information
  33. 8.6.2 Cellectis Business Overview
  34. 8.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  36. 8.6.5 Cellectis Recent Developments
  37. 8.7 Horizon Discovery Plc
  38. 8.7.1 Horizon Discovery Plc Company Information
  39. 8.7.2 Horizon Discovery Plc Business Overview
  40. 8.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  42. 8.7.5 Horizon Discovery Plc Recent Developments
  43. 8.8 Sigma Aldrich
  44. 8.8.1 Sigma Aldrich Company Information
  45. 8.8.2 Sigma Aldrich Business Overview
  46. 8.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  48. 8.8.5 Sigma Aldrich Recent Developments
  49. 8.9 Precision Biosciences
  50. 8.9.1 Precision Biosciences Company Information
  51. 8.9.2 Precision Biosciences Business Overview
  52. 8.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  54. 8.9.5 Precision Biosciences Recent Developments
  55. 8.10 Genscript
  56. 8.10.1 Genscript Company Information
  57. 8.10.2 Genscript Business Overview
  58. 8.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  60. 8.10.5 Genscript Recent Developments
  61. 8.11 Sangamo Biosciences Inc.
  62. 8.11.1 Sangamo Biosciences Inc. Company Information
  63. 8.11.2 Sangamo Biosciences Inc. Business Overview
  64. 8.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  66. 8.11.5 Sangamo Biosciences Inc. Recent Developments
  67. 8.12 Lonza Group Limited
  68. 8.12.1 Lonza Group Limited Company Information
  69. 8.12.2 Lonza Group Limited Business Overview
  70. 8.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  72. 8.12.5 Lonza Group Limited Recent Developments
  73. 8.13 Integrated DNA Technologies
  74. 8.13.1 Integrated DNA Technologies Company Information
  75. 8.13.2 Integrated DNA Technologies Business Overview
  76. 8.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  78. 8.13.5 Integrated DNA Technologies Recent Developments
  79. 8.14 New England Biolabs
  80. 8.14.1 New England Biolabs Company Information
  81. 8.14.2 New England Biolabs Business Overview
  82. 8.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  83. 8.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  84. 8.14.5 New England Biolabs Recent Developments
  85. 8.15 Origene Technologies
  86. 8.15.1 Origene Technologies Company Information
  87. 8.15.2 Origene Technologies Business Overview
  88. 8.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  90. 8.15.5 Origene Technologies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst